Anelixis Therapeutics
Advancing neurodegenerative and autoimmune treatments through targeted biologic therapies
About Anelixis Therapeutics
Anelixis Therapeutics is a biotechnology company focused on developing innovative therapies that target immune system modulation to treat chronic diseases. The company operates in the biopharmaceutical market, primarily serving patients with autoimmune and neurodegenerative conditions. Anelixis Therapeutics employs a research-driven business model, leveraging cutting-edge science to discover and develop novel treatments. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The company aims to address unmet medical needs by advancing its pipeline of therapeutic candidates through clinical trials and regulatory approvals.
Source: Dealroom company dataNews
Open roles
Anelixis Therapeutics in the Cambridge ecosystem
The Anelixis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
BVF Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anelixis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anelixis Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


